During this session on Friday, June 4, 2021, Roche Group made two important announcements that should be of interest to investors. The first one concerns a clinical partnership that it has just set up in the field of liver cancer. As for the second news of the day for the company, it concerns the data concerning giredestrant that it has just published and which are rather positive. Let's take a look at these two pieces of news that could influence the stock.
Thus, the first data that we will deal with today concerning this company concerns the clinical partnership that Roche has just set up in the field of liver cancer treatment.
Indeed, the American biotech Surface Oncology has just announced this afternoon that it was going to implement a collaboration with the Swiss pharmaceutical giant Roche in order to carry out clinical trials concerning the combination of their anti-cancer drugs and for patients who are suffering from hepatocellular carcinoma.
Thus, the tests that will be conducted by the two companies aim to achieve a precise evaluation of the combination of SRF388 which is Surface's experimental anti-IL-27 antibody with Tecentriq and Avastin which are the two flagship anti-cancer drugs developed by Roche.
Surface, whose immunotherapies are designed to achieve a sustained anti-tumor response, is already collaborating with other groups in this sector, including Novartis and GlaxoSmithKline.
Earlier in the day, it was another Roche publication that interested investors, this time concerning the presentation of data about giredestrant. Indeed, the Swiss group announced the presentation of new and updated data regarding this treatment.
Giredestrant is a new generation selective estrogen receptor degrader for people with hormone receptor negative HER-2 breast cancer.
Breast cancer is currently the most common type of cancer worldwide and the HR positive subtype is the most common subtype, accounting for more than 70% of cases.
In particular, the press release issued this morning showed that data from the two early stage trials showed that giredestrant has an encouraging anti-tumor effect and a tolerable safety profile in both the early and advanced settings as reported by the group.
It should also be noted that the precise and detailed data from these various studies will be presented at the American Society of Clinical Oncology or ASCO at the current meeting which started today, June 4 and will end on June 8.
Roche shares will therefore be one of the stocks to watch over the weekend and at the start of trading next Monday.